NeuroBo Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • NeuroBo Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $7.68M, a 73.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $7.68M +$3.25M +73.4% Dec 31, 2023 10-K 2024-03-28
Q4 2022 $4.43M -$26.4M -85.6% Dec 31, 2022 10-K 2024-03-28
Q4 2021 $30.8M +$4.1M +15.4% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $26.7M +$15.1M +130% Dec 31, 2020 10-K 2022-03-31
Q4 2019 $11.6M -$11.3M -49.3% Dec 31, 2019 10-K 2021-04-15
Q4 2018 $22.9M +$6.69M +41.3% Dec 31, 2018 10-K 2019-03-18
Q4 2017 $16.2M +$6.86M +73.6% Dec 31, 2017 10-K 2019-03-18
Q4 2016 $9.32M +$5.66M +155% Dec 31, 2016 10-K 2018-03-20
Q4 2015 $3.66M Dec 31, 2015 10-K 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.